Media type: E-Article Title: Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma Contributor: Schiff, David; Kesari, Santosh; de Groot, John; Mikkelsen, Tom; Drappatz, Jan; Coyle, Thomas; Fichtel, Lisa; Silver, Bruce; Walters, Ian; Reardon, David imprint: Springer Science and Business Media LLC, 2015 Published in: Investigational New Drugs Language: English DOI: 10.1007/s10637-014-0186-2 ISSN: 0167-6997; 1573-0646 Keywords: Pharmacology (medical) ; Pharmacology ; Oncology Origination: Footnote: